Arcus Biosciences, Inc. (RCUS) fundamentals score
Arcus Biosciences is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its most advanced molecules are in Phase 3 registrational studies for various cancer indications and it expects its next wave of clinical-stage molecules to come from its inflammation and autoimmune disease programs.
Pharmaceutical Preparations · Healthcare · Listed on NYSE
Overall: 2.8 out of 10, Unhealthy fundamentals
- Growth: 2.5/10
- Profitability: 1.0/10
- Financial health: 3.6/10
- Earnings quality: 5.1/10
- Valuation: 2.6/10
Scores are calculated from Arcus Biosciences, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10